May 2015

RT @CompBiolPapers: Rapid draft sequencing and real-time nanopore sequencing in a hospital outbreak of Salmonella. http://t.co/CJC43FHK0C

8:05pm May 31st 2015 via Hootsuite

RT @mbeisen: the comment from Eric Lander on @lpachter's blog is horrifying https://t.co/w8p89Z03Pw

7:05pm May 31st 2015 via Hootsuite

Bryce: Genomics Enabled Medicine for Melanoma (GEMM) Trial - 100 pts, 20 different treatment arms. Huge list (40?) of therapies #ASCO15

6:36pm May 31st 2015 via Hootsuite

Bryce: Looked at germline, transcriptome ID alelle-spec expression. Also ID novel fusion in FGFR, all with intact kinase domains #ASCO15

6:32pm May 31st 2015 via Hootsuite

Bryce: 'Pathologists are our best friend': tissue tested hypothesis. '14 PLOS Gen ref http://t.co/3TVlsZ4bLK Clear, marked response #ASCO15

6:31pm May 31st 2015 via Hootsuite

Bryce: Shows IGV in ERFI1 - impacts EGFR, not thought of as oncogenic. Tumor DNA 11% of reads mutant. Showed up in RNA-Seq 80% ASE #ASCO15

6:30pm May 31st 2015 via Hootsuite

Bryce: Shows circos plot - can use it to bring treatment to pts? Integrating all this information, difficult to do, collab w/TGEN #ASCO15

6:28pm May 31st 2015 via Hootsuite

Bryce: Lists analysis methods: gene panels, WES/WGS, long-insert WGS, germline, RNA-Seq, aCGH, cfDNA #ASCO15

6:24pm May 31st 2015 via Hootsuite

Bryce: Also Copy Number + Struct variation: will vary among types as well. CNS and Uveal lower than cutaneous, mucosal #ASCO15

6:23pm May 31st 2015 via Hootsuite

Bryce: And beyond the usual suspects - mut burden in melanomas that also vary among melanoma types (cutaneous vs mucosal vs uveal) #ASCO15

6:22pm May 31st 2015 via Hootsuite

Bryce:Accomplices: NF1 (neg reg of RAS); CDKN2A (familial melanoma); RB1 (resp to BRAFi); TERT; PTEN #ASCO15

6:20pm May 31st 2015 via Hootsuite

Bryce: Genomic clinical heterogeneity: BRAF 45-50% NRAS 25-30% KIT 5% DNAQ/GNA11/BAP1 1% 'None' 15-25% And what do we do for 'none'? #ASCO15

6:18pm May 31st 2015 via Hootsuite

Alan Bryce (Mayo Clinic AZ) "Genomic Approaches in the Discovery of Novel Targets for Melanoma" #ASCO15

6:14pm May 31st 2015 via Hootsuite

Dummer: Cp 1st biopsy to 2nd relapse biopsy, complex but applicable.'13 ref http://t.co/E3lBETRqGQ PDX suggests strategy #ASCO15

6:11pm May 31st 2015 via Hootsuite

Dummer: Subretinal edema raised but also manageable '14 ref http://t.co/cavAap8w4c #ASCO15

6:05pm May 31st 2015 via Hootsuite

Dummer: Increased survival in the combination NEJM '15 http://t.co/b0sPLIscl8 Adverse events in >20% of pts, but can be managed #ASCO15

6:03pm May 31st 2015 via Hootsuite

Dummer: Resistance can be BRAF ampl,/splice vars, reactivating MEK. Thus BRAFi + MEKi combination. NEJM '14 http://t.co/j1HLSGTviW #ASCO15

5:59pm May 31st 2015 via Hootsuite

Dummer: BRAF predicts MEK inhibition '06 ref http://t.co/OjOZL10YhC Yet kinase activity needed '10 ref http://t.co/SvCU5REsOl #ASCO15

5:56pm May 31st 2015 via Hootsuite

Dummer:BRAF V600E orig came from 'brain rapidly accel fibrosarcoma'. '02 ref http://t.co/mu2h9gUmda Germline ras-opathies shown #ASCO15

5:50pm May 31st 2015 via Hootsuite

Reinhard Dummer (Univ Hosp Zurich) "Targeting Patients with the BRAF Mutation: Is Combination Therapy the New Standard?" #ASCO15

5:48pm May 31st 2015 via Hootsuite

Larson: PERSIST-1 myelofibrosis study: Pacritinib selective JAK2/FLT3 inhibitor, cp. to best avail therapy; endpt was spleen vol #ASCO15

9:27am May 31st 2015 via Hootsuite

Larson: HELIOS refractory CLL/SLL PIII trial - ibrutinib + BR vs. placebo + BR, n=289 no del17p, endpt PFS: 80% red. risk of death #ASCO15

9:22am May 31st 2015 via Hootsuite

Larson: PIII trial for relapsed AML started; 120mg/d dose designed around these results #ASCO15

9:20am May 31st 2015 via Hootsuite

Larson: PI trial looked for safe + tolerable dose with inhibition of phospho-FLT3. 127mut, 57wt: 47% response in mutated FLT3 #ASCO15

9:19am May 31st 2015 via Hootsuite

Larson: Oral ASP2215 is a potent mutated FLT3 inhibitor. Used Plasma Inh Assay #ASCO15 '06 ref http://t.co/1VOdarifoL

9:17am May 31st 2015 via Hootsuite

Richard (Dick) Larson (Univ Chicago) "Leukemia, myelodysplasia and transplantation highlights" #ASCO15

9:14am May 31st 2015 via Hootsuite

Cohen: HERACLES trial HER2 positivity in CRC - of 849, treat only 23. 34% response though. Her-2+ ~6% in mCRC #ASCO15

9:12am May 31st 2015 via Hootsuite

Cohen: Pembrolizumab no activity in MMR-pro mCRC #ASCO15

9:10am May 31st 2015 via Hootsuite

Cohen: Mismatch repair (MMR) deficient CRC, 15% early-stage, ~7% in metastatic. dMMR reflex testing is increasing, expanding to BRAF #ASCO15

9:09am May 31st 2015 via Hootsuite

Cohen: (Cp to KRAS/BRAF mut status). Supplementation w/Vit D - no clear evidence will improve outcome in mCRC. Easy to check though. #ASCO15

9:04am May 31st 2015 via Hootsuite

Cohen: CALGB/SWOG 80405: 3 arm, 2.3K pts. Vit D w/highest level had 35% improvement in overall survival. 'One we may modify' #ASCO15

9:03am May 31st 2015 via Hootsuite

Steven Cohen: "Colorectal Cancer Highlights" KRAS/BRAF mut in mCRC trial:'should not do further testing in Stage 3' #ASCO15

9:02am May 31st 2015 via Hootsuite

Garber: Prospective inh. lung ca risk ass'd with germline T790M. in EGFR. Prevalence: about 50% germline, rare in tumor (1%) #ASCO15

8:56am May 31st 2015 via Hootsuite

Garber: her-2 in ER+ vs Triple Neg: NCCN rec'd BRCA testing, and add'l panel screening. NCCN guidelines reinforced. #ASCO15

8:54am May 31st 2015 via Hootsuite

Garber: Uterine corpus ca in BRCA1/2 w/risk-reducing surgery: +1.1% over 10y (BRCA1 ). Guidelines unclear for hysterectomy's role #ASCO15

8:53am May 31st 2015 via Hootsuite

Garber: Women's Health Initiative (WHI) Estrogen alone reduced invasive br ca among black women (self-report and >80% African) #ASCO15

8:49am May 31st 2015 via Hootsuite

Garber: Tamoxifen for br ca prevention, hot flashes most cited reason for stopping (20% or more); ass'd with >BMI #ASCO15

8:47am May 31st 2015 via Hootsuite

Judy Garber "Highlights: Cancer Prevention, Genetics and Epidemiology" P-2 STAR trial for br ca: more 'practice affirming' data #ASCO15

8:46am May 31st 2015 via Hootsuite

RT @GholsonLyon: Controlling for conservation in genome-wide DNA methylation studies http://t.co/J0FTigAQxE #bmcgenomics

8:05am May 31st 2015 via Hootsuite

RT @nextgenseek: The interesting aspects of kallisto: Near-optimal RNA-seq quantification. http://t.co/ZrNucXWaFk #kallisto #RNAseq

7:45am May 31st 2015 via Hootsuite

RT @drbachinsky: A patient's budding cortex -- in a dish? Networking neurons thrive in 3-D human 'organoid' http://t.co/sBKdPIoqsb?

6:10am May 31st 2015 via Hootsuite

RT @drbachinsky: RT @CMichaelGibson: Genetic glitch can predict response to new class of cancer drugs http://t.co/QAwc2cjW3P

5:10am May 31st 2015 via Hootsuite

RT @DocJarad: #ASCO15 Obesity epidemic poised to overtake smoking as main risk factor for cancer http://t.co/vgy2eqJtIv

4:25am May 31st 2015 via Hootsuite

College Has Gotten 12 Times More Expensive in One Generation | Mother Jones http://t.co/MNqY391Yq5

8:10pm May 30th 2015 via Hootsuite

Breen:Q:Examination for protective effect? A:They are doing exactly that, with a low-risk line in a high-risk breed. #ASCO15

7:10pm May 30th 2015 via Hootsuite

Breen:Q:Wolves get cancer? A:Not known for sure; wolves in captivity but may not be comparable to dogs as pets. #ASCO15

7:07pm May 30th 2015 via Hootsuite